AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04299542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous lung biopsy using conventional MDCT
Description: Conventional CT biopsy will be performed using a 64 slice CT scanner. A preliminary plain CT is acquired covering the entire target lesion with a skin marker, and the interventional radiologist would decide on the skin puncture site and the needle pathway. A post-procedural CT scan will be made to detect pneumothorax or pulmonary haemorrhage. All images will be archived in the picture achieving and communication system (PACS).
Study NCT04299542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous lung biopsy CBCT
Description: CBCT guided biopsy will be performed in the angiography suite. A preliminary CBCT (DynaCT) is acquired covering the entire target lesion is first performed. Image data will be displayed and processed using Syngo iGuide system. A potential needle trajectory will be drawn from skin to lesion. Integration of the cross-sectional images and real time fluoroscopy will result in three system positions: one bull's eye view and two progression views. During fluoroscopy, the planned needle trajectory and target will be overlaid on the real time fluoroscopy image. After the needle reaches the target, another CBCT will be performed to confirm needle position. Biopsy using coaxial system and post-procedural CT scans will be performed in similar fashion as the conventional CT group.
Study NCT00108173 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Zyban
Study NCT03838796 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: The patient underwent transfemoral hepatic artery angiography one month after surgery to observe whether there was tumor staining in the liver. If there was suspicious tumor staining, micro-catheter was superselected to the tumor blood vessel, the embolization agents and chemotherapy drugs were injected. If there was no tumor staining, a small amount of embolization agents were slowly injected into the artery.
Study NCT02721225 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fructooligosaccharide
Description: A prebiotics defined as selectively fermented ingredients that allow specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health
Study NCT02976792 — intervention group
Intervention type: PROCEDURE
Intervention: Renal Resistive Index/NephroCheck™test
Description: Renal Resistive Index and NephroCheck™ test before TAVI and after TAVI
Study NCT02890927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardio-geriatric co-management
Description: A comprehensive geriatric assessment on admission will stratify patients in groups:~1. Low risk patients are expected to do well and will not receive co-management.~2. Medium risk patients are expected to develop complications. A geriatric nurse will visit the cardiology wards daily to co-manage these patients aiming to prevent complications by coordinating interdisciplinary care, implementing protocols, perform assessments and bedside education. The geriatric nurse will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning.~3. High risk patients have an acute geriatric syndrome. The geriatric nurse will visit the cardiology wards (see above), and a geriatrician will co-manage the acute geriatric syndrome(s). The geriatrician will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning.
Study NCT02721225 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pocari-Sweat
Description: Commercially used isotonic solution produced by Otsuka Pharmaceuticals Co. Ltd., Tokyo, Japan.
Study NCT02338739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: REC; Outreach if Failure
Description: Routine education and counseling (REC) services, delivered per Kenya Ministry of Health Guidelines; followed by standard of care (SOC) outreach to encourage return to clinic for patients 14 days late for a scheduled visit in year 1.
Study NCT02338739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: REC; SMS + Voucher if Failure
Description: Routine education and counseling services, delivered per Kenya Ministry of Health (MOH) Guidelines; followed by SMS text messages for patients and reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
Study NCT02338739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: REC; Navigator if Failure
Description: REC services, delivered per Kenya MOH Guidelines; followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
Study NCT02338739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS; Outreach if Failure
Description: SMS text messages for patients; followed by SOC outreach for patients 14 days late for a scheduled visit
Study NCT02338739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS; Outreach if Failure; Stop SMS if Success
Description: SMS text messages for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
Study NCT02338739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS; SMS+Voucher if Failure
Description: SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
Study NCT02338739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS; SMS+Voucher if Failure; Stop SMS if Success
Description: SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1, and discontinuation of SMS text messages if never 14 days late
Study NCT01817400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microdialysis
Description: Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two control probes at each site will be perfused at 2.0 µL/min with Ringer's solution to measure basal interstitial testosterone and estradiol levels. One experimental probe at each site will be perfused with the 'compound' 20ug/dl at 2.0 µL/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The 'compound' will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second control probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min.
Study NCT02338739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS; Navigator if Failure
Description: SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
Study NCT02338739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS; Navigator if Failure; Stop SMS if Success
Description: SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
Study NCT02338739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voucher; Outreach if Failure
Description: Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit
Study NCT02338739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voucher; Outreach if Failure; Stop Voucher if Success
Description: Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
Study NCT02338739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voucher; SMS+Voucher if Failure
Description: Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit
Study NCT02338739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voucher; SMS+Voucher if Failure; Stop Voucher if Success
Description: Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
Study NCT02338739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voucher; Navigator if Failure
Description: Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
Study NCT02338739 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voucher; Navigator if Failure; Stop Voucher if Success
Description: Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
Study NCT00333541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Using internet/E-mail for follow-up
Description: follow-up via email link to survey
Study NCT02104609 — intervention group
Intervention type: DRUG
Intervention: Levonorgestrel 1.5mg by mouth once
Description: Levonorgestrel 1.5mg by mouth given on menstrual cycle day 8
Study NCT01817400 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vascepa - Fish Oil
Description: We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.
Study NCT01817400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study NCT01817400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: e will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.
Study NCT01249092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Patients will take 400mg of pentoxifylline three times daily for a total duration of 6 months.
Study NCT02326662 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Description: Autologous neural stem cell transplantation Stem Cell Transplantation by intraspinal and intrathecal injection with 3D matrix as needed
Study NCT03904173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multi-parameter tests
Description: Prosigna Breast Cancer Prognostic Gene Signature Assay (PAM50) risk of recurrence (ROR) analysis CE marked assay termed Prosigna™ using digital bar code technology (NanoString Technologies Inc.).
Study NCT00860743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail
Description: 120 mg of Coenzyme Q10 (orally), 800 mg of Superoxide Dismutase (orally), 400 IU of Vitamin E (orally) before exposure to intermittent hypoxia. Two doses of 1 g of Vitamin C in 50 cc of saline IV (in the vein) before and after exposure to intermittent hypoxia.
Study NCT02902887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Controlled Intermittent Alternate Occlusion (CIAO ) glasses
Description: Monitored CIAO therapy glasses
Study NCT02208752 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercises
Description: exercise program on strengthening the rotator cuff muscles and motor control of the scapula
Study NCT00932126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03758309
Description: Oral PF-03758309 will be administered in capsules (once or twice daily) until toxicity, progressive disease, or patient refusal to continue on therapy. The starting dose is 1 mg once daily.
Study NCT00066365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: given by inhalation, dosage escalation Level 1 Dose: 240 micrograms, Level 2 Dose: 1,000 micrograms, and Level 3 Dose: 1,750 micrograms.
Study NCT00066365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: thoracotomy
Study NCT02208752 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: exercise program on strengthening the rotator cuff muscles and motor control of the scapula
Study NCT04027881 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit Together and REad
Description: STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
Study NCT00764296 — intervention group
Intervention type: OTHER
Intervention: no treatment
Description: collection of samples of wound biofilm in Acute and Chronic Wounds
Study NCT00764296 — intervention group
Intervention type: OTHER
Intervention: no treatment
Description: collection of samples for the evaluation of Wound Biofilm in Acute and Chronic Wounds
Study NCT02244931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Servomatic™ assisting device
Description: Servomatic™ is an hand controlled motorized device assisting to propel the wheelchair .
Study NCT03020173 — intervention group
Intervention type: OTHER
Intervention: Laboratory study
Description: Laboratory analysis to determine composition of granulosa and oocytes
Study NCT02146664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1033
Description: Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
Study NCT02146664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
Study NCT04553302 — intervention group
Intervention type: OTHER
Intervention: This study does not contain any intervention.
Description: This study does not contain any intervention.
Study NCT03944031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3372689
Description: Administered orally.
Study NCT03944031 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]LSN3316612
Description: Administered IV.
Study NCT03887546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle trainer
Description: The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O).
Study NCT03887546 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory exercise
Description: Respiratory exercise program involving nasal breathing and maximum exhalation during 12 weeks, 5 days/week, 15 minutes/day.
Study NCT03094104 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: News items with spin
Description: Interpretation of news items with spin
Study NCT03094104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: News items without spin
Description: Interpretation of news items without spin
Study NCT00143689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine
Description: See Detailed Description.
Study NCT01289119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets
Study NCT02758704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High stress
Description: Generation of a stressful environment during a neonatal intubation procedure.
Study NCT02758704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low stress
Description: Absence of stressful stimuli during neonatal intubation procedure
Study NCT02758704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation on mannequin
Description: Endotracheal intubation will take place at the simulation centre on a mannequin.
Study NCT02758704 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation on mannequin
Description: Endotracheal intubation will take place at the simulation centre on a mannequin.
Study NCT03542123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroTronik CANS Therapy® System
Description: The NeuroTronik CANS Therapy® System is a percutaneous, catheter-based, bedside electrical stimulation system. The System consists of the single-use, disposable NeuroCatheter™ and NeuroCatheter™ Placement Kit, along with the reusable, bedside NeuroModulator™ Development System, and the NeuroTronik CANS Therapy™ Cable.
Study NCT01289119 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo to alogliptin
Description: Alogliptin placebo-matching tablets.
Study NCT04203498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabiximols
Description: Nabiximols is a complex botanical medicine formulated from extracts of the cannabis plant that contains the principal cannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and also contains minor constituents, including other cannabinoid and non-cannabinoid plant components, such as terpenes, sterols, and triglycerides.Nabiximols will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
Study NCT02244931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E.Motion© assisting device
Description: E.Motion© is an hand controlled motorized device assisting to propel the wheelchair .
Study NCT04203498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match nabiximols will be presented as an oromucosal spray containing the excipients ethanol and propylene glycol (50% v/v) with colorings and flavored with peppermint oil (0.05% v/v). Each spray will deliver 100 microliters (μL) containing no active ingredients. Placebo will be self-administered by participants as an oromucosal spray in the morning and evening, up to a maximum of 12 sprays per day for 12 weeks.
Study NCT01289119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to alogliptin
Description: Alogliptin placebo-matching tablets.
Study NCT01289119 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Stable metformin dose
Study NCT01289119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Stable metformin dose
Study NCT01289119 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pioglitazone
Description: Stable pioglitazone dose
Study NCT01289119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Stable pioglitazone dose
Study NCT02313441 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Remote Ischemic Pre-Conditioning
Description: The blood pressure cuff was inflated to a pressure of 200 mm Hg for 5 minutes, followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated 3 times by the resident doctors in the pre-cath room
Study NCT02313441 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Pre-Conditioning
Description: The blood pressure cuff was inflated to a pressure of 200 mm Hg for 5 minutes, followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated 3 times by the resident doctors in the pre-cath room
Study NCT03787706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Patients will receive dry needling over active trigger points in the upper trapezius muscle
Study NCT03787706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Patients will receive a manual compression for 30seconds over active trigger points in the upper trapezius muscle
Study NCT02987543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: 300 mg (2x 150 mg tablets) twice daily
Study NCT02987543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enzalutamide
Description: 160 mg (4 x 40 mg capsules) once daily
Study NCT02987543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abiraterone acetate
Description: 1,000 mg (4 x 250 mg tablets) once daily
Study NCT02987543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abiraterone acetate
Description: 1,000 mg (2 x 500 mg tablets) once daily